Vericel Corp (VCEL) Short Interest Update

Vericel Corp (NASDAQ:VCEL) saw a large drop in short interest in the month of January. As of January 12th, there was short interest totalling 1,093,372 shares, a drop of 23.5% from the December 29th total of 1,430,058 shares. Based on an average daily volume of 1,001,242 shares, the days-to-cover ratio is presently 1.1 days. Currently, 3.1% of the company’s shares are short sold.

Several large investors have recently made changes to their positions in the stock. Perkins Capital Management Inc. raised its holdings in shares of Vericel by 2.9% during the 4th quarter. Perkins Capital Management Inc. now owns 578,950 shares of the biotechnology company’s stock valued at $3,155,000 after buying an additional 16,350 shares during the period. Bank of Montreal Can purchased a new stake in shares of Vericel during the 4th quarter valued at about $140,000. Citadel Advisors LLC purchased a new stake in shares of Vericel during the 3rd quarter valued at about $235,000. Archon Capital Management LLC raised its holdings in shares of Vericel by 95.7% during the 3rd quarter. Archon Capital Management LLC now owns 2,617,004 shares of the biotechnology company’s stock valued at $15,702,000 after buying an additional 1,279,925 shares during the period. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Vericel during the 3rd quarter valued at about $328,000. Institutional investors and hedge funds own 33.15% of the company’s stock.

Shares of Vericel (NASDAQ VCEL) opened at $7.30 on Monday. The company has a market capitalization of $239.62, a PE ratio of -8.30 and a beta of 3.02. The company has a current ratio of 2.50, a quick ratio of 2.22 and a debt-to-equity ratio of 0.44. Vericel has a twelve month low of $2.35 and a twelve month high of $7.55.

Vericel (NASDAQ:VCEL) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01. The business had revenue of $14.26 million for the quarter. Vericel had a negative return on equity of 265.45% and a negative net margin of 45.11%. research analysts predict that Vericel will post -0.6 earnings per share for the current year.

A number of equities analysts have recently commented on the company. BTIG Research set a $8.00 price objective on Vericel and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Piper Jaffray Companies restated an “overweight” rating and issued a $9.00 price objective on shares of Vericel in a report on Tuesday, January 2nd. Finally, ValuEngine downgraded Vericel from a “hold” rating to a “sell” rating in a report on Friday, December 1st.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/29/vericel-corp-vcel-short-interest-update.html.

About Vericel

Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply